Business
PRO: Record sales and robust growth, with new clinical approvals fueling future expansion
PRO: Record sales and robust growth, with new clinical approvals fueling future expansion
About this update from Promimic Ab
Record quarterly sales and 48% rolling 12-month growth driven by new product approvals and license deals. Cash flow remains negative, but strong market trends and new technologies support continued expansion.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.